BMS-754807 , 99% , 1001350-96-4

Synonym(s):
(2S)-1-[4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-2-Pyrrolidinecarboxamide;BMS 754807

CAS NO.：1001350-96-4

Empirical Formula: C23H24FN9O

Molecular Weight: 461.49

MDL number: MFCD18633202

PRODUCT Properties

• Density: 1.58
• storage temp.: room temp
• solubility: ≥23.05 mg/mL in DMSO; insoluble in H2O; ≥27.75 mg/mL in EtOH
• form: powder
• color: white to beige
• optical activity: [α]/D -86 to -96°, c = 1 in methanol

Description and Uses

BMS 754807 is a reversible, orally bioavailable dual inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases (IC₅₀s = 1.8 and 1.7 nM, respectively). It has minimal effect against an array of other tyrosine and serine/threonine kinases. BMS 754807 inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro. It inhibits the growth of tumor xenografts in mice and this effect is often enhanced by combination therapy with other chemotherapeutics. Predictive biomarkers, including elevated IGF-1R expression, for effectiveness of BMS 754807 have been delineated.

BMS 754807 is a reversible, orally bioavailable dual inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively). It has minimal effect against an array of other tyrosine and serine/threonine kinases. BMS 754807 inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro. It inhibits the growth of tumor xenografts in mice and this effect is often enhanced by combination therapy with other chemotherapeutics. Predictive biomarkers, including elevated IGF-1R expression, for effectiveness of BMS 754807 have been delineated.[Cayman Chemical]